Citigroup
ABCL icon

Citigroup’s AbCellera Biologics ABCL Stock Holding History

Citigroup’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$29.6K Buy
8,472
+123
+1% +$443 ﹤0.01% 4704
2025
Q4 		$28.6K Buy
8,349
+2,603
+45% +$11.6K ﹤0.01% 4769
2025
Q3 		$28.9K Sell
5,746
-8,710
-60% -$38.4K ﹤0.01% 4682
2025
Q2 		$49.6K Buy
14,456
+10,119
+233% +$25.2K ﹤0.01% 4760
2025
Q1 		$9.67K Sell
4,337
-8,279
-66% -$23.7K ﹤0.01% 5206
2024
Q4 		$37K Buy
12,616
+7,382
+141% +$20.6K ﹤0.01% 5154
2024
Q3 		$13.6K Sell
5,234
-74,055
-93% -$205K ﹤0.01% 5243
2024
Q2 		$235K Buy
79,289
+75,249
+1,863% +$285K ﹤0.01% 3804
2024
Q1 		$18.3K Sell
4,040
-4,064
-50% -$20.7K ﹤0.01% 5055
2023
Q4 		$46.3K Buy
8,104
+3,842
+90% +$17.8K ﹤0.01% 4564
2023
Q3 		$19.6K Sell
4,262
-3,759
-47% -$22.9K ﹤0.01% 4400
2023
Q2 		$51.8K Buy
8,021
+2,884
+56% +$19.7K ﹤0.01% 4629
2023
Q1 		$38.7K Sell
5,137
-2,532
-33% -$23K ﹤0.01% 4328
2022
Q4 		$77.7K Sell
7,669
-2,409
-24% -$27.8K ﹤0.01% 4120
2022
Q3 		$100K Sell
10,078
-22,646
-69% -$248K ﹤0.01% 4091
2022
Q2 		$349K Buy
32,724
+21,702
+197% +$184K ﹤0.01% 3494
2022
Q1 		$107K Sell
11,022
-2,229
-17% -$21.1K ﹤0.01% 4380
2021
Q4 		$189K Buy
13,251
+7,471
+129% +$113K ﹤0.01% 4394
2021
Q3 		$116K Sell
5,780
-1,867
-24% -$33K ﹤0.01% 4362
2021
Q2 		$168K Buy
7,647
+7,447
+3,724% +$205K ﹤0.01% 4308
2021
Q1 		$7K Buy
+200
New +$7.97K ﹤0.01% 5795

Other funds holding ABCL

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Citigroup's ABCL Position: Q1 2026 in Review

Citigroup increased its AbCellera Biologics (ABCL) stake by 1.5% in Q1 2026, buying an estimated $443 and bringing the position to 8,472 shares worth $29.6K. The position accounts for ﹤0.01% of the portfolio, ranked #4704.

Citigroup first reported a position in ABCL in Q1 2021 and has held it in 21 quarters since. The position peaked at $349K in Q2 2022. 138 funds tracked by Wall St. Rank hold ABCL as of Q1 2026.

  • Citigroup held 8,472 shares of AbCellera Biologics worth $29.6K as of Q1 2026.
  • Citigroup bought 123 AbCellera Biologics shares in Q1 2026, an estimated $443.
  • AbCellera Biologics made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #4704 holding.
  • Citigroup first reported a position in AbCellera Biologics in Q1 2021 and has held it in 21 quarters since.
  • Citigroup's AbCellera Biologics position peaked at $349K in Q2 2022.
  • 138 funds tracked by Wall St. Rank held AbCellera Biologics as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.